98%
921
2 minutes
20
Nonhuman primate models are valuable in biomedical research. However, reference data for clinical pathology parameters in cynomolgus and rhesus monkeys are limited. In the present study, we established hematologic and biochemical reference intervals for healthy cynomolgus and rhesus monkeys anesthetized with ketamine hydrochloride. A total of 142 cynomolgus monkeys (28 males and 114 females) and 42 rhesus monkeys (22 males and 20 females) were selected and analyzed in order to examine reference intervals of 20 hematological and 16 biochemical parameters. The effects of sex were also investigated. Reference intervals for hematological and biochemical parameters were separately established by species (cynomolgus and rhesus) and sex (male and female). No sex-related differences were determined in erythrocyte-related parameters for cynomolgus and rhesus monkey housed in indoor laboratory conditions. Alkaline phosphatase and gamma glutamyltransferase were significantly lower in females than males in both cynomolgus and rhesus monkeys aged 48-96 months. The reference values for hematological and biochemical parameters established herein might provide valuable information for researchers using cynomolgus and rhesus monkeys in experimental conditions for biomedical studies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081622 | PMC |
http://dx.doi.org/10.1186/s42826-019-0006-0 | DOI Listing |
Cell Rep
September 2025
National Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China; State Key Laboratory of Respiratory Health and Multimorbidity, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China; Center for
LP-98 is a lipopeptide HIV fusion inhibitor showing strong treatment and pre-exposure prophylaxis efficacies in non-human primates. In this study, we further characterized its pharmacokinetics, long-lasting antiviral activity, and post-exposure prophylaxis (PEP) efficacy using 62 macaques. In cynomolgus macaques, LP-98 achieved high concentrations (C) with a half-life (T) of ∼31 h, and sustained an effective therapeutic concentration for two weeks post-injection.
View Article and Find Full Text PDFImmunity
August 2025
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address:
The H5N1 avian influenza virus clade 2.3.4.
View Article and Find Full Text PDFVaccine
July 2025
IAVI, New York, NY, USA. Electronic address:
Uganda recently declared the end of its sixth Sudan virus (SUDV) outbreak; the prior outbreak having ended just two years earlier. Efficacious vaccines are licensed for protection against Ebola virus (EBOV), but there is no evidence that these afford clinical protection against other orthoebolaviruses. While EBOV has been extensively characterized in humans and animal models, the evidence base for SUDV is more limited due to the lower frequency of outbreaks and cases to date.
View Article and Find Full Text PDFJ Am Assoc Lab Anim Sci
May 2025
1Department of Biomedical Sciences, Ross University School of Veterinary Medicine, Basseterre, Saint Kitts and Nevis.
A 19-y-old, colony-born, female African green monkey (Chlorocebus sabaeus) presented for recurrent swelling measuring 11 × 5 × 4 cm on the right thigh, around the stifle, which started 5 y previous, resulting in lameness. The affected area had alopecia and crusting and felt lobulated on palpation. Radiographic evaluation revealed multiple foci of well-circumscribed, soft-tissue mineralization within the subcutis and underlying muscles.
View Article and Find Full Text PDFSci Transl Med
July 2025
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.
The clinically approved seasonal influenza vaccines provide only 10 to 60% efficacy, necessitating strategies to improve vaccine performance. Here, we explored strategies for improving influenza vaccine efficacy using gene-based vaccines and mucosal boosting strategies in nonhuman primates. All vaccinated cynomolgus macaques were primed with the clinical quadrivalent inactivated virus (QIV) vaccine.
View Article and Find Full Text PDF